NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
Show detailsOVERVIEW
Introduction
Oxybutynin is a synthetic anticholinergic agent that is used for treatment of urinary incontinence and overactive bladder syndrome. Oxybutynin has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Background
Oxybutynin (ox" i bue' ti nin) is synthetic anticholinergic that has specificity for the M1, M2 and M3 subtypes of the muscarinic acetylcholine receptor which are commonly found in bladder smooth muscle. Oxybutynin is used largely for the treatment of overactive bladder and for symptoms of frequency and urge incontinence. Oxybutynin was approved for use in the United States in 1975 and is still widely used. It is available in regular and extended release tablets as well as oral solutions, syrups, and transdermal creams in various generic forms and under the trade name Ditropan. A transdermal patch formulation is available under the brand name Oxytrol. The usual adult oral dose is 10 to 20 mg daily in divided doses or in a single extended release tablet form. Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety, restlessness and in some instances agitation and delusions. Anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.
Hepatotoxicity
Like other anticholinergic agents, oxybutynin has not been linked to episodes of liver enzyme elevations or clinically apparent liver injury. A major reason for its safety may relate to the low daily dose. It is metabolized in the liver via the CYP 3A4 enzyme system and can cause significant drug-drug interactions.
References on the safety and potential hepatotoxicity of anticholinergics are given together after the Overview section on Anticholinergic Agents.
Drug Class: Anticholinergic Agents
PRODUCT INFORMATION
REPRESENTATIVE TRADE NAMES
Oxybutynin – Generic, Oxytrol®
DRUG CLASS
Anticholinergic Agents
Product labeling at DailyMed, National Library of Medicine, NIH
CHEMICAL FORMULA AND STRUCTURE
DRUG | CAS REGISTRY NUMBER | MOLECULAR FORMULA | STRUCTURE |
---|---|---|---|
Oxybutynin | 5633-20-5 | C22-H31-N-O3 | ![]() |
- Treatments for overactive bladder: focus on pharmacotherapy.[J Obstet Gynaecol Can. 2012]Treatments for overactive bladder: focus on pharmacotherapy.Geoffrion R, UROGYNAECOLOGY COMMITTEE.. J Obstet Gynaecol Can. 2012 Nov; 34(11):1092-1101.
- Review Flavoxate[LiverTox: Clinical and Researc...]Review Flavoxate. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
- Review An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.[Clin Ther. 1999]Review An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.Goldenberg MM. Clin Ther. 1999 Apr; 21(4):634-42.
- Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.[Int Urogynecol J Pelvic Floor ...]Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.Anderson RU, MacDiarmid S, Kell S, Barada JH, Serels S, Goldberg RP. Int Urogynecol J Pelvic Floor Dysfunct. 2006 Sep; 17(5):502-11. Epub 2006 May 3.
- Review Fesoterodine[LiverTox: Clinical and Researc...]Review Fesoterodine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
- Oxybutynin - LiverToxOxybutynin - LiverTox
Your browsing activity is empty.
Activity recording is turned off.
See more...